Keywords:
Antibodies; viral; neutralizing; pregnancy; complications infections; prevention and control; respiratory syncytial virus; vaccines; immunology
Abstract:
To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).